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Objectives The purpose of this study was to evaluate the efﬁcacy and outcome of transcatheter
aortic valve implantation (TAVI) in patients with low-ﬂow, low-gradient aortic stenosis (LG-AS).
Background Patients with LG-AS have a poor prognosis with medical treatment and a high risk for
surgical aortic valve replacement.
Methods Between January 2009 and June 2010, a total of 1,302 patients underwent TAVI for severe
AS and were prospectively included in the multicenter German TAVI registry.
Results LG-AS was present in 149 patients (11.4%; mean age: 80.2  6.3 years). In this subgroup,
the EuroSCORE was signiﬁcantly higher (26.8  16.6 vs. 20.0  13.3; p  0.0001) compared with pa-
tients with high-gradient AS (HG-AS). The procedural success rate (LG-AS: 95.3% vs. HG-AS: 97.5%; p 
0.13) and the rate of TAVI-associated complications were comparable in both groups (new pacemaker:
27.0% vs. 28.1%; p  0.76; cerebrovascular events: 3.4% vs. 3.1%, p  0.83). However, post-operative
low-output syndrome occurred more frequently in the LG-AS-group (LG-AS: 14.9% vs. HG-AS: 5.7%, p 
0.0001), and mortality at 30 days and 1 year was signiﬁcantly higher in this subgroup (LG-AS: 12.8% and
36.9% vs. HG-AS: 7.4% and 18.1%; p  0.001 and p  0.0001, respectively). Post-operative New York
Heart Association functional class improved, and self-assessed quality of life increased signiﬁcantly, dem-
onstrating a substantial beneﬁt in the LG-AS group at 30 days and 1 year after TAVI.
Conclusions In high-risk patients with LG-AS, TAVI is associated with a signiﬁcantly higher mortality
at 30 days and at 1 year. However, long-term survivors beneﬁt from TAVI with functional improve-
ment and a signiﬁcantly increased quality of life. Therefore, in view of the poor prognosis with med-
ical treatment, TAVI should be considered an option in high-risk patients with LG-AS. (J Am Coll
Cardiol Intv 2012;5:552–9) © 2012 by the American College of Cardiology Foundation
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553Transcatheter aortic valve implantation (TAVI) has been
introduced as a less invasive treatment for severe aortic
stenosis (AS) (1). Since its introduction, the technology has
been rapidly adopted. With increasing operator experience
and the development of novel devices, results have improved
significantly. Recently, randomized controlled trials have
demonstrated favorable outcome after TAVI in nonsurgical
and high-risk surgical patients compared with standard
treatment (2,3). However, despite these advances, current
experience regarding safety and efficacy of TAVI in subsets
of patients with additional risk factors is still limited.
See page 560
Patients with severe aortic stenosis (AS), but a moderate
transvalvular gradient (valve area 1 cm2, mean gradient
40 mm Hg) and reduced left ventricular (LV) function
(ejection fraction 40%), constitute such a high-risk subset
(low-flow, low-gradient AS [LG-AS]) for surgical aortic
valve replacement (AVR) (4). When treated medically, this
subgroup has a dismal prognosis, with poor long-term
survival (5–7). Although TAVI could offer a viable treat-
ment option for these patients, the feasibility and outcome
of the procedure have not been studied in this subgroup of
patients with aortic valve disease. Patients with LG-AS present
with a particularly unfavorable combination of risk factors, and
it is questionable whether they benefit from the procedure.
Therefore, the purpose of this study was to evaluate the
feasibility and outcome of TAVI in this subgroup based on data
from a prospective multicenter German Transcatheter Aortic
Valve Interventions Registry (8,9).
Methods
Study design and collection of data. The German Trans-
atheter Aortic Valve Interventions Registry is a prospective
ulticenter registry designed to monitor the current use of
AVI and the procedural characteristics, the efficacy, and
he outcome of patients undergoing TAVI (8,9). The
egistry was initiated by the scientific interest of the partic-
pating institutions and receives no funding from industrial
ompanies but is financed by the Institut für Herzinfarkt-
orschung (IHF) in Ludwigshafen. A total of 27 tertiary
ardiovascular centers contributed data to the registry. Data
ere collected at each site using standardized case report
orms to record demographic and clinical characteristics as
ell as procedural and follow-up data. Follow-up was
btained at 30 days and at 1 year based on the medical
ecords and on physician and patient interviews. The
nvestigators had full access to the data and control of the
nalysis.
Inclusion criteria and treatment. The registry design and
nclusion criteria have been reported previously (8,10). In
rief, all patients with severe AS undergoing TAVI were dligible for inclusion. The diagnosis of severe AS and the
ndication for TAVI were based upon the established
riteria: aortic valve area 1 cm2 (with or without aortic
alve regurgitation), a transvalvular gradient 40 mm Hg,
nd either age80 years and a logistic EuroSCORE20%
r a logistic EuroSCORE 20% if 1 of the following was
resent: porcelain aorta, cirrhosis of the liver of pulmonary
nsufficiency (forced expiratory volume at 1 s 1 l). Severe
ow-gradient aortic stenosis was defined according to cur-
ent guideline criteria if the aortic valve area was 1 cm2 in
the presence of a mean transvalvular gradient 40 mm Hg
and a reduced LV ejection fraction 40% (4). Pre-
interventional patient screening included transthoracic and
transesophageal echocardiography as well as dobutamine
stress echocardiography (DSE) for exclusion of pseudoste-
nosis and determination of severity if LG-AS was sus-
pected. The baseline operative risk was estimated by the
logistic EuroSCORE, and the
choice of treatment was made at
the discretion of the treating
physician, surgeon, and/or the
heart team.
Device. At the time of patient
nrollment, 2 devices for TAVI
rocedures were commercially
vailable in Germany: the balloon-
xpandable Edwards SAPIEN (23
m and 26 mm; recently, the
dwards SAPIEN XT composed
f a cobalt-chromium stent; Ed-
ards Lifesciences, Irvine, Califor-
ia) and the Medtronic Core-
alve (Medtronic, Minneapolis,
innesota), a porcine pericardial
issue valve in a self-expanding ni-
inol stent frame. The 29-mm Ed-
ards SAPIEN XT was not avail-
ble during the time covered by the registry. The implantation
rocedures of both devices have been reported previously
11,12). For implantation of the balloon-expandable device,
he Ascendra delivery catheter was used for transapical access,
nd the Retroflex, or recently the Novaflex, delivery catheter
or transfemoral access.
Endpoints. Major clinical endpoints were analyzed accord-
ng to the criteria proposed by the Valve Academic Research
onsortium (VARC) (13). The primary endpoint of the
tudy was all-cause mortality at 30 days and 1 year.
ortality at both time points was further subdivided into
ardiovascular and noncardiovascular mortality. According
o VARC definitions, all unknown deaths were considered
s cardiovascular in origin.
The secondary endpoint evaluated procedural character-
stics (procedural success, device type and access route,
Abbreviations
and Acronyms
AS  aortic stenosis
AVR  aortic valve
replacement
DSE  dobutamine stress
echocardiography
EQ-5D-VAS  EuroQol-5D
visual analogue scale
HG-AS  high-gradient aortic
stenosis
LG-AS  low-flow, low-
gradient aortic stenosis
LV  left ventricular
NYHA  New York Heart
Association
TAVI  transcatheter aortic
valve implantationevice function) as well as the rate of adverse events
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554(myocardial infarction, stroke, acute kidney injury, bleeding
and vascular complications, permanent pacemaker require-
ment, and post-operative low cardiac output syndrome [a
state of decreased cardiac output due to severely depressed
LV function leading to secondary multiple organ failure]).
After device implantation, the degree of aortic regurgitation
was classified angiographicly into 4 grades based upon the
method of Sellers et al. (14). Clinical benefit endpoints
evaluated New York Heart Association (NYHA) functional
class and quality of life using the EuroQol-5D visual
analogue scale (EQ-5D-VAS). Clinical benefit was assessed
within the first 30 days (NYHA functional class, EQ-5D-
VAS) and at 1 year (EQ-5D-VAS) after TAVI.
Statistics. Continuous data are presented as mean  SD,
nd categorical variables are depicted as percentages and
umbers. Categorical variables were compared by means of
he chi-square test, and continuous variables using the
-tailed Wilcoxon rank sum test. Two-sided p values0.05
ere considered statistically significant. Mortality at 30 days
as calculated by the Kaplan-Meier survival analysis
ethod. The vital status of patients already discharged or
ransferred to a rehabilitation program was verified by
ollow-up calls performed by the IHF. Survival curves were
onstructed for time-to-event variables using Kaplan-Meier
stimates and compared by the log-rank test.
Univariate Cox proportional hazards regression analysis
as performed among established predictors of 30-day
ortality. In addition, ejection fraction was dichotomized to
bove and below 30%. All covariates with a p value of 0.1
ere included in the multivariate Cox regression model.
ackward stepwise elimination was subsequently performed
o identify independent predictors for 30-day mortality. A
ovariate was removed from the model if the p value
xceeded 0.10. All p values 0.05 were considered statisti-
ally significant. In multivariate models, adjustments were
ade for the potential confounders of age, sex, diabetes,
hronic obstructive pulmonary disease, 3-vessel coronary
rtery disease, pulmonary hypertension, peripheral vascular
isease, previous cardiac procedures, previous cardiac de-
ompensations 12 months, previous myocardial infarc-
ions, EuroSCORE 20%, LV ejection fraction 30%,
nd LG-AS. All statistical analyses were performed using
he SAS statistical package, version 9.1 (SAS Institute,
ary, North Carolina).
esults
Patient population. Between January 2009 and June 2010, a
total of 1,302 TAVI procedures were performed in 27
participating hospitals. The mean number of patients in-
cluded per hospital was 49 (range: 1 to 268). In the overall
group, 149 patients were diagnosed with LG-AS according
to current guideline criteria (4). The remaining 1,153patients presented with severe AS and a high transvalvular
gradient 40 mm Hg.
Patient demographics and baseline characteristics are
listed in Table 1. Compared with patients with high-
gradient AS (HG-AS), those in the LG-AS group were
significantly younger (80.9  6.3 years vs. 81.9  6.2 years;
 0.001) and presented with a higher number of comor-
bidities. This is reflected by a significantly higher logistic
EuroSCORE in the LG-AS group compared with patients
with HG-AS (26.8  16.6 vs. 20.0  13.2; p  0.0001).
atients in both groups were severely symptomatic at the
ime of the procedure. There was a significantly higher
umber of patients with NYHA functional class IV in the
G-AS group (LG-AS: 28.2% vs. HG-AS: 16.0%, p 
.001).
Interventional characteristics. Preoperative hemodynamics
and characteristics of the TAVI procedure are presented in
Tables 2 and 3. Prior to device implantation, the aortic valve
area was severely reduced in both groups (LG-AS: 0.69 
0.18 cm2 vs. HG-AS: 0.67 0.37 cm2; p 0.01). Ejection
Table 1. Baseline Characteristics
Low-Gradient AS
(n  149)
High-Gradient AS
(n  1,153) p Value
Age, yrs 80.2 12.2 81.9 6.2 0.01
Male 85 (57) 459 (39.8) 0.001
Body mass index, kg/m2 27.0 9.7 26.9 10.1 0.4
Logistic EuroSCORE, % 26.8 16.6 20.0 13.7 0.0001
Previous medical history
Chronic obstructive pulmonary
disease
39 (26.2) 289 (25.1) 0.77
Peripheral vascular disease 36 (30.9) 237 (20.6) 0.01
Pulmonary hypertension 120 (81.1) 738 (64.7) 0.0001
Systolic pulmonary pressure,
mm Hg
47.3 15.2 44.8 33.9 0.01
CAD 119 (89.9) 670 (58.3) 0.0001
1-vessel CAD 27 (18.1) 254 (22.1) 0.27
2-vessel CAD 26 (17.4) 153 (13.3) 0.17
3-vessel CAD 66 (44.3) 263 (22.9) 0.0001
Previous PCI 75 (50.3) 385 (33.5) 0.0001
Previous myocardial infarction 38 (25.7) 168 (14.6) 0.001
Previous cardiac surgery 41 (27.5) 243 (21.1) 0.07
CABG 38 (25.5) 198 (17.18) 0.08
Valve 1 (0.67) 46 (3.99) 0.01
Diabetes mellitus 62 (41.6) 391 (34) 0.07
Mitral regurgitation II° 71 (48.0) 373 (32.6) 0.01
Chronic renal failure* 96 (64.6) 699 (60.6) 0.37
Stroke or TIA, intracranial
hemorrhage
15 (10.1) 88 (7.6) 0.3
Permanent pacemaker/
deﬁbrillator
31 (20.8) 158 (13.8) 0.05
Values are mean SD or n (%). *Chronic renal failure: glomerular filtration rate 60 ml/min/
1.73 m2.
AS aortic stenosis; CABG coronary artery bypass grafting; CAD coronary artery disease;PCI percutaneous coronary intervention; TIA transient ischemic attack.
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555fraction and mean transvalvular gradient were significantly
lower in the LG-AS group compared with the HG-AS
group (37.8  14.5% and 31.3  13.3 mm Hg vs. 54.5 
13.7% and 49. 9 16.5 mm Hg; both p  0.0001). In both
groups, the majority of interventions were performed as
elective procedures. The rate of urgent TAVI procedures
was significantly higher (LG-AS: 24.8% vs. HG-AS: 14.5;
p  0.01) in patients with LG-AS. Regarding the preferred
evice or access route, no differences in LG-AS patients
ere observed compared with HG-AS patients. The
edtronic CoreValve was used in the majority of proce-
ures (LG-AS: 85.9% vs. HG-AS: 79.9%; p  0.08),
hereas the Edwards SAPIEN device was used less fre-
uently (LG-AS: 14.1% vs. HG-AS: 19.8%; p  0.1).
hus, the majority of procedures were performed trans-
emorally in both groups (LG-AS: 87.0% vs. HG-AS
6.4%; p  0.6). A transapical access was preferred in 8.1%
LG-AS) and 9.6% (HG-AS), respectively. Other access
outes (transaxillary, transaortic) were used in the remaining
.0% of patients in both groups.
Rates of death and predictors of early mortality after
TAVI. Thirty-day mortality after TAVI was significantly
igher in patients with LG-AS compared with HG-AS
12.8% vs. 7.4%, p  0.001) (Fig. 1A). At the 1-year
ollow-up, the rate of death from any cause was 36.9% in the
G-AS group as compared with 18.1% in the HG-AS
roup (p  0.0001) (Fig. 1B). The rate of death from
ardiovascular causes at 1 year was also significantly higher
n the LG-AS group than in the HG-AS group (LG-AS:
4.2% vs. HG-AS 16.6%; p  0.0001) (Table 4).
Cox proportional hazards models were used to assess the
alue of LG-AS and covariates for the prediction of early
ortality after TAVI (Table 5). All covariates potentially
ssociated with death after TAVI were included in a
ultivariate Cox model. Hazard ratios and their 95%
onfidence intervals are reported from the proportional
azards models. After adjustment for confounding vari-
bles, predictive factors for mortality after TAVI were the
Table 2. Pre-Operative Hemodynamics
Hemodynamics
Low-Gradient AS
(n  149)
High-Gradient AS
(n  1,153) p Value
Ejection fraction 37.8 14.4 54.5 13.7 0.0001
Aortic valve area, cm2 0.69 0.18 0.67 0.37 0.01
Mean pressure gradient
(echo), mm Hg
31.3 13.3 49.9 16.52 0.0001
Peak-to-peak gradient
(invasive), mm Hg
37.2 20.4
(n 121)
65.7 32.35
(n 829)
0.0001
Minor calciﬁcation* 12 (8.1) 54 (4.7) 0.08
Moderate calciﬁcation* 52 (34.9) 337 (29.5) 0.18
Severe calciﬁcation* 85 (57.0) 752 (65.8) 0.05
Values are mean SD or n (%). *Grading according to Rosenhek et al. (24).
AS aortic stenosis.resence of a LG-AS, a logistic EuroSCORE 20, previ-us myocardial infarction, and decompensated heart failure
ithin the preceding 12 months.
Post-operative clinical course. The 30-day post-operative
clinical course is detailed in Table 6. In patients with
LG-AS, duration of post-operative treatment in the inten-
sive care unit was comparable to patients with HG-AS
(3.0  3.0 vs. 3.0  2.9; p  0.36). Characteristic
AVI-associated complications occurred with similar fre-
uencies in both groups during hospital treatment: implan-
ation of a new permanent pacemaker due to atrioventricular
onductance disturbances was required in LG-AS and
G-AS patients in 27.0% and 28.1% (p  0.76), respec-
ively. Cerebrovascular complications were reported in 3.4%
LG-AS) and 3.1% (HG-AS; p  0.83). Vascular compli-
Table 3. Secondary Endpoint: Procedural Characteristics
Low-Gradient AS
(n  149)
High-Gradient AS
(n  1,153)
p
Value
Decision for TAVI made by
“Heart Team”
112 (75.2) 824 (71.5) 0.34
Priority of procedure
Elective 108 (72.5) 970 (84.1) 0.001
Urgent 37 (24.8) 167 (14.5) 0.01
Emergency 4 (2.7) 11 (1.0) 0.06
Duration of procedure, min 90.5 51.5 89.3 49.9 0.85
Access route for valve
implantation
Transfemoral 131 (87.9) 996 (86.4) 0.6
Apical 12 (8.1) 111 (9.6) 0.54
Transaortic 1 (0.7) 9 (0.8) 0.89
Transaxillary 5 (3.4) 37 (3.2) 0.92
Device
Medtronic CoreValve 128 (85.9) 921 (79.9) 0.08
26 mm 53 (41.4) 441 (47.9) 0.17
29 mm 75 (58.6) 480 (52.1) 0.17
Edwards SAPIEN 21 (14.1) 228 (19.8) 0.08
23 mm 6 (28.6) 110 (48.2) 0.08
26 mm 15 (71.4) 118 (51.8) 0.08
Immediate result
Successful device implantation 142 (95.3%) 1,123 (97.5) 0.13
Conversion to surgery 3 (2.0) 14 (1.2) 0.42
Procedure aborted 4 (2.7) 15 (1.3) 0.19
Device function
Post-operative gradient, mm Hg 5.6 5.3 6.1 6.9 0.84
Residual AR 105 (70.9) 773 (68.0) 0.48
No AR 43 (29.1) 363 (32.0) 0.48
AR I° 79 (53.4) 617 (54.3) 0.83
AR II° 26 (17.6) 138 (12.1) 0.06
AR III° 0 (0) 16 (1.4) 0.15
AR IV° 0 (0) 2 (0.1) 0.61
Additional procedures
Adjunctive PCI 10 (6.2) 49 (4.3) 0.18
Values are n (%) or mean SD.
AR aortic regurgitation; TAVI transcatheter aortic valve implantation; other abbreviationsas in Table 1.
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556cations associated with transfemoral access occurred more
frequently in LG-AS patients, although these were not
significant (LG-AS: 28.4% vs. HG-AS: 23.5%; p  0.12).
However, complications potentially associated with reduced
left ventricular function (e.g., low cardiac output syndrome)
were more common in the LG-AS group: Post-operative
low-output syndrome was reported in 14.9% of LG-AS
patients versus 5.7% of HG-AS patients (p  0.0001). Thus,
in the LG-AS group, a significantly higher proportion re-
quired mechanical circulatory support (LG-AS: 5.4% vs. HG-
AS: 1.7%; p  0.001) and cardiopulmonary resuscitation was
more often necessary (LG-AS: 12.8% vs. HG-AS: 5.3%; p 
Figure 1. Survival at 30 Days and 1 Year After TAVI in LG-AS
Versus HG-AS
Kaplan-Meier survival curves for patients with severe aortic stenosis (AS)
after transcatheter aortic valve implantation (TAVI) stratiﬁed by transvalvu-
lar gradient. In patients with low-ﬂow, low-gradient aortic stenosis (LG-AS),
survival at 30 days (A) and at 1 year (B) is signiﬁcantly lower compared
with patients with high-gradient aortic stenosis (HG-AS) (log-rank test:
p  0.0194 and p  0.0001, respectively).0.001).Clinical beneﬁt endpoints at 30 days and 1 year. Details on
pre- and post-operative functional status are listed in
Table 7. At baseline, the majority of patients with LG-AS
and HG-AS were in NYHA functional class III or IV. In
the LG-AS group, there was a significantly higher propor-
tion of patients in NYHA functional class IV compared
with the HG-AS group (LG-AS: 28.2% and HG-AS:
16.0%, p 0.001). Within 30 days after TAVI, the NYHA
functional class improved in both groups, with the majority
of patients reaching NYHA functional class I and II
(NYHA I: LG-AS 46.7% vs. HG-AS 55.1, p  0.16;
NYHA II: LG-AS 22.7 vs. HG-AS 28.2, p  0.31).
However, a significantly higher proportion of LG-AS
patients remained in NYHA functional class IV at 30 days
after TAVI (LG-AS: 12.0% vs. HG-AS 4.5%; p  0.01).
Quality of life as measured with the EQ-5D-VAS
improved significantly in both groups at 30 days (Table 5).
Quality of life was reassessed after 1 year, demonstrating a
larger benefit in long-term survivors in the LG-AS group
compared with the HG-AS group. Thus, in both groups
TAVI achieves comparable early and long-term postopera-
tive functional results according to EQ-5D-VAS.
Discussion
The present report is based on data from the German
Transcatheter Aortic Valve Interventions Registry, which
Table 4. Primary Endpoints: Mortality and MACCE at 30 Days and
After 1 Year
Low-Gradient AS
(n  149)
High-Gradient AS
(n  1,153) p Value
In-hospital mortality 24 (16.1) 83 (7.2) 0.001
Follow-up at 30 days
Completeness of follow-up 148 (99.3) 1,140 (98.9) 0.50
30-day all-cause mortality 19 (12.8) 84 (7.4) 0.001
Cardiovascular cause 17 (11.4) 75 (6.8) 0.001
Noncardiovascular cause 2 (1.3) 7 (0.6) 0.91
Follow-up at 1 year
Completeness of follow-up 141 (94.6) 1,087 (94.3) 0.85
1-year all-cause mortality 52 (36.9) 197 (18.1) 0.0001
Cardiovascular cause 48 (34.2) 180 (16.6) 0.0001
Noncardiovascular cause 4 (2.7) 16 (1.5) 0.29
Combined endpoints at 30 days
MACCE (death, MI, stroke) 10 (6.6) 26 (2.3) 0.0001
Combined MAE (MACCE, re-OP,
bleeding, dialysis)
11 (7.4) 40 (3.5) 0.01
Combined endpoints at 1 year
(after discharge)
MACCE (death, MI, stroke) 33 (23.5) 143 (13.2) 0.001
Combined MAE (MACCE, re-OP,
bleeding, dialysis)
34 (24.3) 164 (15.1) 0.01
Values are n (%) or mean SD
AS  aortic stenosis; MACCE  major adverse cardiac and cerebral event(s); MAE majoradverse event(s); MImyocardial infarction; re-OP reoperation.
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557includes the biggest-ever reported series of patients treated
with TAVI. Recent publications from this registry reflect
the current state of adoption of the technique in Germany
and have demonstrated a high success rate of TAVI asso-
ciated with a moderate rate of complications (8,9).
LG-AS is an infrequent condition observed in approxi-
mately 5% of all patients with severe AS (7,15–17). How-
ever, these patients represent a controversial and challenging
subpopulation with a particularly poor prognosis when
undergoing conservative or surgical treatment (5–7,18).
TAVI is an alternative treatment option in this difficult
subgroup. However, due to the paucity of clinical data, the
feasibility and outcome of TAVI have not yet been inves-
tigated in these patients. Since it is still uncertain whether
patients with LG-AS benefit from less invasive treatment,
we aimed at evaluating the feasibility and outcome of TAVI
in this high-risk subgroup with aortic valve disease.
TAVI procedure and complication rate. The observations
ade in this analysis can be summarized to 3 major
ndings. One important primary finding is that TAVI can
e performed safely in LG-AS despite the unfavorable risk
rofile of these patients. Although this subgroup presented
ith a higher rate of comorbidities, a lower ejection fraction,
nd hence a higher EuroSCORE (LG-AS: 26.8  16.6%
s. HG-AS: 20.0  13.2%; p0.0001), TAVI was associ-
ted with a similarly high procedural success rate and a
imilar rate of procedure-associated complications com-
ared with patients with HG-AS (Table 6) (8,9).
The majority of procedures in both groups were per-
ormed transfemorally (LG-AS: 89.6% vs. HG-AS: 91.3%;
 0.6) employing the Medtronic CoreValve. Cerebrovas-
cular events were reported in 3.1% of patients with LG-AS
versus 3.4% of patients with HG-AS (p  0.83), a finding
Table 5. Predictors of Mortality After TAVI: Cox Proportional
Hazards Model
Hazard Ratio 95% CI p Value
Age 0.987 0.960–1.013 0.32
Female 0.722 0.527–0.987 0.04
Diabetes 0.975 0.717–1.325 0.87
COPD 1.009 0.724–1.407 0.96
Pulmonary hypertension 1.029 0.734–1.442 0.87
3-vessel CAD 0.921 0.614–13.81 0.69
PVD 1.307 0.940–1.818 0.11
Previous cardiac procedures 0.615 0.388–0.976 0.039
Previous decompensation
within 12 months
1.678 1.219–2.311 0.0015
Myocardial infarction 1.592 1.116–2.271 0.01
EuroSCORE 20 1.747 1.200–2.543 0.004
LV ejection fraction 30% 1.088 0.711–1.664 0.67
Low-gradient AS 2.201 1.466–3.303 0.0001
CI confidence interval; COPD chronic obstructive pulmonary disease; LV left ventricular;
PVD peripheral vascular disease; other abbreviations as in Tables 1 and 3.that is in good agreement with other reports (19,20). Asdemonstrated by diffusion-weighted magnetic resonance
imaging studies, new clinically imperceptible perfusion def-
icits occur frequently during TAVI due to atherothrombotic
emboli. Our data suggest that despite the higher-risk profile
of the LG-AS group, TAVI is not associated with higher
rate of cerebrovascular events in these patients.
However, in patients with LG-AS, a higher rate of
post-operative low cardiac output syndromes (LGAS:
14.9% vs. HGAS: 5.7%; p 0.0001), a more frequent
requirement for mechanical circulatory support devices in-
cluding intra-aortic counterpulsation (LG-AS: 5.4% vs.
HG-AS: 1.7%; p  0.0001) and a higher rate of post-
operative cardiopulmonary resuscitations (LG-AS: 12.8%
vs. HG-AS: 5.3%; p  0.001). This increased rate of low
cardiac output in the LG-AS subgroup is related to the
Table 6. Secondary Endpoints at 30 Days: Early Complications Classified
According to VARC (13)
Low-Gradient AS
(n  149)
High-Gradient AS
(n  1,153)
p
Value
Duration of treatment in ICU, days 3.0 3.0 3.0 2.9 0.36
Post-operative complications
Low cardiac output 22 (14.9) 65 (5.7) 0.0001
Conservative 14 (9.5) 46 (4.0) 0.01
Mechanical assist device (e.g., IABP) 8 (5.4) 19 (1.7) 0.0001
Myocardial infarction 2 (1.3) 5 (0.4) 0.15
Stroke 5 (3.4) 35 (3.1) 0.83
Transient ischemic attack (24 h) 0 (0) 16 (1.4) 0.05
Minor stroke (Rankin score 2) 1 (0.7) 5 (0.43) 0.33
Major stroke (Rankin score 2) 5 (3.4) 16 (1.4) 0.59
Acute kidney injury (modiﬁed RIFLE
classiﬁcation)
Stage 1 (creatinine increase
150% to 200%)
22 (17.7) 118 (11.8) 0.06
Stage 2 (creatinine increase
200% to 300%)
5 (4.0) 45 (4.5) 0.81
Stage 3 (creatinine increase 300%) 2 (1.6) 35 (3.5) 0.27
Vascular complications 42 (28.4) 269 (23.5) 0.12
Major 8 (5.4) 40 (3.5) 0.25
Minor 34 (23.0) 229 (20.0) 0.40
Bleeding complications 30 (20.1) 168 (14.6) 0.08
Life-threatening or disabling
(or 4 RBC units)
11 (36.7) 13 (7.5) 0.31
Major bleeding (or 2 or 3 RBC units) 15 (50) 109 (64.9) 0.25
Minor bleeding (1 RBC unit) 4 (13.3) 46 (27.6) 0.28
Cardiopulmonary resuscitation 19 (12.8) 61 (5.3) 0.001
Permanent pacemaker/deﬁbrillator
(total)
56 (37.8) 417 (36.6) 0.77
Permanent pacemaker/deﬁbrillator
(new)
40 (27.0) 324 (28.1) 0.76
Pulmonary embolism 3 (2.0) 18 (1.6) 0.67
Values are mean SD or n (%).
AS aortic stenosis; IABP intra-aortic balloon pump counterpulsation; ICU intensive care
unit; RBC packed red blood cells; RIFLE risk, injury, failure, loss, end-stage renal disease;VARC Valve Academic Research Consortium.
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558pre-operatively impaired LV function and has also been
observed after surgical AVR in LG-AS (5–7).
The rate of newly implanted permanent pacemakers in
this study is higher than in many other reports. In the
current registry, a permanent pacer was implanted in 27.0%
of patients with LG-AS and 28.1% with HG-AS (p 
0.76). This number is in line with the results recently
reported by Khawaja et al. (21), who reported a permanent
pacemaker requirement in up to 33.3% of 270 patients
undergoing TAVI. By contrast, Eltchaninoff et al. (19) and
Piazza et al. (20) reported a rate of 9.3% and 11.8%,
respectively. Apart from device-related issues, the higher
rate of pacemaker implantations in this registry can possibly
be explained by the lower threshold of the treating cardiol-
ogist regarding safety issues in order to avoid complications
associated with third-degree atrioventricular block (8).
Thus, this observation reflects the currently limited knowl-
edge concerning mechanisms and factors leading to this
unpredictable complication after TAVI.
Mortality and clinical beneﬁt endpoints. A second major
finding is that TAVI in LG-AS is associated with a
significantly higher mortality at 30 days (LG-AS: 12.8% vs.
HG-AS: 7.4%; p 0.001) and at 1 year (LG-AS: 36.9% vs.
G-AS: 18.1%; p  0.0001). Among all patients included
n the registry, Cox regression analysis determined the
resence of LG-AS as a significant predictor of early
ortality, which is associated with a proportional hazard of
.2. Other predictors of mortality were previous cardiac
ecompensations 12 months (hazard ratio: 1.7), previous
yocardial infarctions (hazard ratio: 1.6), and a logistic
Table 7. Clinical Benefit Endpoints: NYHA Functional Class and
Quality of Life During Follow-Up
Low-Gradient AS
(n  149)
High-Gradient AS
(n  1,153)
p
Value
Functional status at baseline and 30 days
NYHA functional class (baseline)
I 3 (2.0) 14 (1.2) 0.43
II 5 (3.4) 117 (10.2) 0.01
III 99 (66.4) 830 (72.6) 0.12
IV 42 (28.2) 183 (16.0) 0.001
NYHA functional class (30 days)
I 35 (46.7) 391 (55.1) 0.16
II 17 (22.7) 200 (28.2) 0.31
III 14 (18.7) 87 (12.3) 0.11
IV 9 (12.0) 32 (4.5) 0.01
Quality of life beneﬁt (EQ-5D-VAS)
Baseline 0.57 0.32 0.63 0.27 0.12
30 days 0.64 0.26* 0.69 0.24* 0.41
1 year 0.69 0.28* 0.68 0.25* 0.48
Values are n (%) or mean SD. *Values significantly different from baseline (p 0.0001).
AS aortic stenosis; EQ-5D-VAS EuroQol-5D visual analogue scale; NYHANew York Heart
Association.uroSCORE 20 (hazard ratio: 1.7). Putting these find-ngs in perspective with other published data, the 30-day
ortality observed in the present study lies within the range
f 11% to 21% of early mortality reported in multiple other
eports (6,7,16). In another recent paper by Gotzmann et al.
22) reviewing a small series of patients undergoing TAVI,
n increased mortality was observed in the LG-AS sub-
roup. However, in this report, surviving patients experi-
nced a symptomatic benefit and functional improvement.
he TAVI approach in patients with reduced LV function
s further supported by a recent report from Clavel et al.
23), who observed better recovery of LV function after
AVI compared with surgical AVR. These findings suggest
hat the TAVI approach is feasible in patients with LG-AS
nd leads to clinical improvement. However, this observa-
ion requires further validation by clinical data.
Third, patients with LG-AS benefit from TAVI, with a
eduction in symptoms of heart failure at 30 days and a
ignificant improvement in quality of life at 30 days and at
year. EQ-5D-VAS demonstrates a lower quality of life at
aseline in the LG-AS group compared with the HG-AS
roup. During follow-up, EQ-5D-VAS improved signifi-
antly in both subgroups, reaching comparable values at 1
ear. Although this improvement may partly be related to
he higher mortality in the LG-AS subgroup, it suggests a
arger quality-of-life benefit from TAVI in surviving pa-
ients with LG-AS. Thus, in view of the lack of treatment
ptions and the dismal prognosis of LG-AS, the increased
ortality in patients with LG-AS after TAVI may be
onsidered acceptable (5).
Study limitations. First, this report reflects the experience in
limited number of patients. Although this is the largest
eries of patients undergoing TAVI for LG-AS published
o date to our knowledge, further data on efficacy and
utcome in this difficult subgroup are required. Second,
emodynamic assessment was performed by DSE, and
atients with pseudostenosis were excluded from TAVI.
owever, data on contractility reserve derived from DSE
re not available in this registry. These data should be taken
nto consideration when designing future studies as they
ay yield valuable information regarding risk stratification
n patients with LG-AS. Third, the present report is limited
o reporting follow-up at 30 days and 1 year. Further studies
hould focus on longer follow-up and should include data
n post-operative recovery of LV function, which may also
erve as an indicator for better outcome. Fourth, this version
f the registry evaluated the logistic EuroSCORE, but not
he Society of Thoracic Surgeons–predicted risk score of
ortality, thus making comparisons with other data more
ifficult.
onclusions
High-risk patients with LG-AS benefit from less invasive
therapy. Since conservative treatment does not improve
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559survival, these patients should be considered for TAVI,
which can be performed safely with a moderate complica-
tion rate. Although the mortality is significantly higher after
TAVI for LG-AS, long-term survivors benefit from the
procedure with significantly improved quality of life.
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Appendix
List of participating centers (in order of numbers
of included patients)
Klinikum Siegburg: U. Gerckens, Universität Leipzig Her-
zzentrum: G. Schuler, Herzzentrum Ludwigshafen: R.
Zahn, Universitätsklinikum Essen: H. Eggebrecht, Cardio
Vasculäres Centrum (CVC) Frankfurt Sankt Katharinen:
H. Sievert, Krankenhaus der barmherzigen Brüder Trier:
K.E. Hauptmann, Asklepios Klinik St Georg Hamburg:
K.H. Kuck, Klinikum Links der Weser Bremen, R. Ham-
brecht, Segeberger Kliniken GmbH: G. Richardt, Univer-
sitätsklinikum Bonn, Med Klinik und Poliklinik II: G.
Nickenig, Elisabeth-Krankenhaus Essen: C.H. Naber,
Klinikum Schwabing, München: S. Sack, Universitätsklini-
kum Jena: H.R. Figulla, Augustinum Klinik München: M.
Block, Städt Klinikum München Klinik Bogenhausen: E.
Hoffmann, Robert-Bosch-Krankenhaus, Stuttgart: U.
Sechtem, HELIOS Klinikum Wuppertal: H. Gülker, Uni-
versitäts Klinikum Regensburg: G. Riegger, Krankenhaus
München—Neuperlach: H. Mudra, Herzzentrum Bad
Krozingen: F.J. Neumann, Universitätsklinikum Freiburg:
C. Bode, Klinikum Coburg: J. Brachmann.
